TNYA241220C5000
- 0.20
- -0.05-20.00%
Tenaya Therapeutics Newsroom
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $19
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $18
Tenaya Therapeutics Analyst Ratings
Positive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy Rating
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)
TD Cowen Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
TD Cowen Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Tenaya Therapeutics Is Maintained at Buy by Chardan Capital
Tenaya Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $15 to $19
Buy Rating Affirmed for Tenaya Therapeutics Amid Positive DSMB Update and Strong Financial Position
Promising Developments and Safety Enhancements Bolster Buy Rating for Tenaya Therapeutics' Gene Therapy
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
TD Cowen Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Leerink Partners Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $8
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $19
Promising Developments and DSMB Approval Drive Buy Rating for Tenaya Therapeutics
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Tenaya Therapeutics Price Target Maintained With a $16.00/Share by Canaccord Genuity
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $16